# A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct07115043/  
OnCo record `nct07115043` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Rilvegostomig in melanoma and non-small-cell lung cancer, run by AstraZeneca, now recruiting.

## Summary

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07115043 by AstraZeneca, with 120 participants planned, started 2025-07-29 and due to reach its primary completion in 2029-10-02. Interventions recorded: AZD6750, rilvegostomig. Conditions listed: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07115043
- Phase: 1/2
- Setting: A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors
- Sponsor: AstraZeneca
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07115043: https://clinicaltrials.gov/study/NCT07115043

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07115043.json